Dr. Mark Kris reports on new agents that overcome acquired resistance to EGFR TKIs in patients with NSCLC who have a T790 mutation, and recommends rebiopsying patients to identify who would benefit.

What are the pros and cons of using thrombolytics in PE patients?

Recent trials show the first successful treatments for idiopathic pulmonary fibrosis. Exciting news for this fatal disease, but success rates must be interpreted with caution, says Dr. Andrew Shorr.

Dr. Mark Kris reports on 2 studies on MET inhibition in NSCLC that underscore the importance of defining the patient population who would benefit from a targeted therapy.

Art Caplan speaks with ethicist and author Dr. Barron Lerner about his new book, his physician father, and how medical ethics have changed over the years.

The FDA’s proposed new rule would allow for sweeping new regulations of these products. Will that be good for public health?

Four leading oncologists discuss the top studies from ASCO 2014 and how immunotherapy is reshaping cancer care and practice.

Many people die with a pacemaker intact. In less developed countries, recycling these pacemakers might help save lives. A bioethicist talks about the risk and reward.

Muscle mass and function are reduced in cancer as a consequence of therapy, malnutrition, and physical inactivity. Dr. David Kerr sees reason enough to prescribe exercise in addition to chemo.

Dr. Eric Topol talks with CEO of 23andMe Anne Wojcicki about how her company is challenging the status quo in healthcare.